Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …

Highlights•GLP-1 analogs can cross the blood–brain barrier and stimulate the GLP-1
receptor in the brain.•Stimulation of the GLP-1 receptor has shown effects on mitochondrial …

Allosteric ligands bind to G protein-coupled receptors (GPCRs; also known as seven-
transmembrane receptors) at sites that are distinct from the sites to which endogenous …

The glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) are
members of the secretin-like class B family of G-protein-coupled receptors (GPCRs) and …

Abstract Glucagon-like peptide-1 (7–36) amide (GLP-1) is a secreted peptide that acts as a
key determinant of blood glucose homeostasis by virtue of its abilities to slow gastric …

Objectives Even with great advances in modern medicine and therapeutic agent
development, the search for effective antidiabetic drugs remains challenging. Coumarins are …

Glucagon‐like peptide‐1 (7‐36) amide (GLP‐1) is a 30‐residue peptide hormone released
from intestinal L cells following nutrient consumption. It potentiates the glucose‐induced …